Navigation Links
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
Date:7/22/2009

ure. Talk to your doctor immediately if you experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin.

If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Talk to your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, anemia, and weight gain. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Some patients have experienced visual changes while taking ACTOS.

Some people, particularly women, are at higher risk of having bone fractures while taking ACTOS. Other side effects may include cold-like symptoms, headache, sinus infection, muscle pain, tooth disorder, and sore throat.

Please visit the Takeda Pharmaceuticals North America, Inc. Web site at www.tpna.com for Complete Prescribing Information including the boxed warning about heart failure.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical compa
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for ... today that Dr. James F. Pingpank will present ... Therapies, to be held February 21-23, 2009. ...
... Mass., Feb. 18 ,Abbott ( NYSE: ABT ) ... Hepatitis C (HCV) collaboration with a first-in-human study,evaluating ... of chronic,HCV. The objectives of the trial ... was discovered as part of a worldwide alliance,between ...
Cached Medicine Technology:Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 2Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 3Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 4Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 2Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 "Women struggle ... These hormonal daily changes begin as early as 15, ... their lives negotiating the ups and downs of hormone ... thin or even healthy sizes seems to rage against ... As a woman in her 40's begin to face ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... The Outlier Series announced the next short e-Book ... one of the exceptional women featured in the series’ ... . The title of the upcoming mini e-Book is ... . McClendon is currently a full-time physician’s assistant, and ... WeTV show, Raising Sextuplets. , Jenny was chosen as ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as ... can have devastating effects on those who develop it. ... they are not produced by electrical anomalies in the ... estimated that the numbers of persons suffering PNES may ... , Dr. Lorna Myers, Director of the Northeast ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... CINCINNATI, July 28 LCA-Vision Inc. (Nasdaq: LCAV ... Lasik Plus ((R)) brand, today announced financial and operating results for ... , Second Quarter 2009 Operational and Financial Results ... , Revenue was $31.7 million compared with ...
... , , , MINNEAPOLIS, July ... and marketer of state-of-the-art cardiac surgery products, announced today that it ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , ... Focus on Healthcare Conference at the Millennium Broadway Hotel in New ...
... , GLEN ROCK, N.J., July 28 ... of Fingertip Formulary Accounts((R)), a state-of-the art web-based platform ... data and resources at an account level. The ... now provides immediate, real-time integrated provider-level data that includes ...
... , , DENVER, ... caregiver workflow in healthcare environments, today announced that Alegent ... ThinIdentity solution throughout its healthcare system. The first installation ... Iowa. A 278-bed facility, Mercy Hospital has over 1,000 ...
... July 28 According to a new market,research report, ,Drug-Device ... the total drug-device,combination market is expected to be worth US$18.54 ... for nearly 30.9% of the total revenues.,The global market is ... 2014. , Browse 144 market data ...
... ... first analog frame grabber for the National Instruments CompactRIO embedded real-time platform at the ... NIWeek the world,s leading graphical system design conference and exhibition hosted by National Instruments. ... Irvine, CA ...
Cached Medicine News:Health News:LCA-Vision Reports Second Quarter Financial Results 2Health News:LCA-Vision Reports Second Quarter Financial Results 3Health News:LCA-Vision Reports Second Quarter Financial Results 4Health News:LCA-Vision Reports Second Quarter Financial Results 5Health News:LCA-Vision Reports Second Quarter Financial Results 6Health News:LCA-Vision Reports Second Quarter Financial Results 7Health News:LCA-Vision Reports Second Quarter Financial Results 8Health News:LCA-Vision Reports Second Quarter Financial Results 9Health News:LCA-Vision Reports Second Quarter Financial Results 10Health News:LCA-Vision Reports Second Quarter Financial Results 11Health News:LCA-Vision Reports Second Quarter Financial Results 12Health News:LCA-Vision Reports Second Quarter Financial Results 13Health News:LCA-Vision Reports Second Quarter Financial Results 14Health News:ATS Medical to Participate at Upcoming Investor Conferences 2Health News:Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... (DHEA-S) is the sulfate ester of DHEA, ... conversion of DHEA in adrenal and extradrenal ... secreted by the adrenal cortex, and is ... DHEA possesses relatively weak androgenic activity, which ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: